Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

4,000

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

November 30, 2025

Conditions
COVID-19Vaccines
Interventions
BIOLOGICAL

AdCLD-CoV19-1 OMI

3000 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular administration in the deltoid muscle

BIOLOGICAL

Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)

1000 participants will receive investigational product (Comirnaty Bivalent) via intramuscular administration in the deltoid muscle

Trial Locations (17)

Unknown

The Medical City-Iloilo, Iloilo City

West Visayas State University Medical Center, Iloilo City

Tropical Disease Foundation, Inc., Makati

Far Eastern University - Nicanor Reyes Medical Foundation, Quezon City

Dong-a University Hospital, Busan

Kyungpook National University Hospital, Daegu

Chungnam National University Hospital, Daejeon

Chonnam National University Hospital, Gwangju

Hallym University Dongtan Sacred Heart Hospital, Gyeonggi-do

Korea University Ansan Hospital, Gyeonggi-do

The Catholic University of Korea, ST. Vincent's Hospital, Gyeonggi-do

Gachon University Gil Medical Center, Incheon

Inha University Hospital, Incheon

Hallym University Kangnam Sacred Heart Hospital, Seoul

Korea University Guro Hospital, Seoul

The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul

Veterans Health Service Medical Center, Seoul

All Listed Sponsors
lead

Cellid Co., Ltd.

INDUSTRY

NCT05993325 - Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers | Biotech Hunter | Biotech Hunter